SHAKEDIA POPE: Open Payments
NPI 1427600642 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$734 in 27 payments from 8 companies in 2025. Trend: 2023 $999 · 2024 $915 · 2025 $734
Food & beverage: $734
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $351 |
| Lilly USA, LLC | 9 | $216 |
| Galderma Laboratories, L.P. | 3 | $51 |
| MERZ NORTH AMERICA, INC. | 1 | $45 |
| ABBVIE INC. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| REVANCE THERAPEUTICS, INC. | 1 | $14 |
Products named: Wegovy, ZEPBOUND, MOUNJARO, BOTOX, TRINTELLIX, DYSPORT, CONTRAVE, DAXXIFY.
Industry payments across FL — which companies pay providers there.
